MedDataX Logo

Time Course of Procalcitonin and C Reactive Protein in Septic Patients Under Treatment With Corticosteroids

NCT ID: NCT00141973

Last Updated: 2008-05-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Study Classification

OBSERVATIONAL

Study Start Date

2004-11-30

Study Completion Date

2005-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A systemic treatment with corticosteroids has been advocated for various bacterial infectious diseases. Since the production of CRP is down-regulated by corticosteroids, a smaller increase or a more rapid decrease of this acute phase protein will:

1. suggest attenuated systemic inflammation, but
2. does not necessarily reflect adequate therapy of the infection.

For several reasons (good diagnostic tool for sepsis, induction not decreased by immunosuppressive therapy), procalcitonin could be a better marker for activity of sepsis in patients under corticosteroids. As this issue has not yet been examined the investigators will prospectively study the time-course of PTC and CRP in a well-defined septic patient group, that in adjunction to antibiotic therapy also received systemic corticosteroid treatment and compare it to a similar group without corticosteroid treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Procalcitonin in Diagnosis of Sepsis in Critically Ill Patient

NCT04105400

Sepsis, Severe
UNKNOWN

Neonatal Procalcitonin Intervention Study

NCT00854932

Sepsis
UNKNOWN NA

Procalcitonin as a Tool to Shorten Antibiotic Therapy in the ICU

NCT01494675

Sepsis
COMPLETED NA

Procalcitonin to Guide Antibiotic Stop in Neurocritical Care Patients.

NCT03683693

Sepsis
UNKNOWN NA

The Effect of Moderate-Dose Steroid Therapy in Sepsis

NCT01275638

Sepsis
COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Acute exacerbation of chronic obstructive pulmonary disease (COPD) due to bacterial pneumonia

Exclusion Criteria

* Chronic systemic use of corticosteroids
Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Brahms SA, D-16761 Hennigsdorf bei Berlin

UNKNOWN

Sponsor Role collaborator

Ospedale Regionale Bellinzona e Valli

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andreas Perren, MD

Role: PRINCIPAL_INVESTIGATOR

Ospedale Regionale Bellinzona e Valli, CH-6500 Bellinzona

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ospedale Regionale Bellinzona e Valli

Bellinzona, Canton Ticino, Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CE1408

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Procalcitonin in Diagnosing Bacteremia in the Emergency Department
NCT00174122 UNKNOWN
Procalcitonin Monitoring May Decrease Antibiotic Use in the Intensive Care Unit
NCT01085994 UNKNOWN
Procalcitonin-Guided Decision Making to Shorten Antibiotic Therapy in Suspected Neonatal Early-Onset Sepsis
NCT00926497 COMPLETED NA
Stress Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock
NCT02266589 COMPLETED PHASE3
Impact of Hydrocortisone Administration on White Blood Cell Gene Expression in Patients With Severe Sepsis
NCT00185783 COMPLETED
Clinical Characteristics and Risk Factors for In-Hospital Mortality in Surgical Patients With Abdominal Sepsis
NCT06756750 COMPLETED
Diagnostic and Prognostic Value of Serial Procalcitonin (PCT) Measurements in Critically Ill Patients
NCT01362920 COMPLETED
Endothelium in Severe Sepsis
NCT00793442 COMPLETED
Early Intravenous Hydrocortisone in Sepsis
NCT06217939 RECRUITING NA
Procalcitonin-Guided Antimicrobial Discontinuation
NCT00250666 COMPLETED PHASE4
Effects of Fludrocortisone and Hydrocortisone in Healthy Volunteers With Aldosterone Induced Suppression
NCT00673270 TERMINATED PHASE1/PHASE2
COronary Microcirculation and Troponin Elevation in Septic Shock
NCT06294730 COMPLETED
C-reactive Protein Information and Blood Cultures for Emergency Department Patients With Sepsis
NCT03714841 UNKNOWN NA
Procalcitonin and Endotoxin Sequential Levels to Optimize the Treatment of Bloodstream Infections
NCT00870623 COMPLETED
CRP and PCT as Predictors of Sepsis Cause
NCT05605275 COMPLETED
Procalcitonin Monitoring Sepsis Study
NCT01523717 COMPLETED
Effects of Stress Doses of Hydrocortisone on Coagulation Dysfunction in Patients With Septic Shock
NCT02114710 COMPLETED PHASE3
Procalcitonin in Cirrhotic Patients at High Risk for Sepsis
NCT01578226 COMPLETED
Activated Protein C and Corticosteroids for Human Septic Shock
NCT00625209 COMPLETED PHASE3
Procalcitonin to Shorten Antibiotics Duration in ICU Patients
NCT01379547 UNKNOWN PHASE3
Procalcitonin in Diagnosis of Bacterial Infections in Young Infants
NCT03509727 COMPLETED
Septic Shock em Steroids
NCT01047670 UNKNOWN PHASE2/PHASE3
The Impact of Sepsis on Long-term Outcomes in Critical Ill Children With Sepsis
NCT06323226 RECRUITING
Procalcitonin Level and Kinetics in Children With Bacterial Infections
NCT00714402 COMPLETED
Evaluation of Corticosteroid Therapy in Childhood Severe Sepsis - a Randomised Pilot Study
NCT00732277 COMPLETED PHASE2